Travere Therapeutics Inc
$ 42.96
-4.62%
02 Jun - close price
- Market Cap 4,188,400,000 USD
- Current Price $ 42.96
- High / Low $ 44.70 / 42.37
- Stock P/E N/A
- Book Value 1.07
- EPS -0.50
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.69 %
- 52 Week High 48.61
- 52 Week Low 13.88
About
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Analyst Target Price
$54.14
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-19 | 2025-10-30 | 2025-08-06 | 2025-05-01 | 2025-02-20 | 2024-10-31 | 2024-08-01 | 2024-05-06 | 2024-02-15 | 2023-11-07 | 2023-08-03 |
| Reported EPS | -0.4 | 0.37 | 0.59 | 0.13 | -0.19 | -0.47 | -0.46 | -0.65 | -1.51 | -0.94 | 2.27 | -0.77 |
| Estimated EPS | -0.3 | -0.04 | -0.08 | 0.04 | -0.39 | -0.3786 | -0.54 | -0.72 | -0.79 | -0.92 | 0.04 | -0.93 |
| Surprise | -0.1 | 0.41 | 0.67 | 0.09 | 0.2 | -0.0914 | 0.08 | 0.07 | -0.72 | -0.02 | 2.23 | 0.16 |
| Surprise Percentage | -33.3333% | 1025% | 837.5% | 225% | 51.2821% | -24.1416% | 14.8148% | 9.7222% | -91.1392% | -2.1739% | 5575% | 17.2043% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TVTX
2026-06-02 12:40:08
Everest Medicines and Travere Therapeutics have entered an exclusive licensing agreement for civorebrutinib, a potential best-in-class BTK inhibitor for rare kidney diseases. Travere will develop and commercialize the drug outside of China and certain East/Southeast Asian countries, with Everest receiving an upfront payment of $112.5 million and up to $1.03 billion in milestones. The agreement aims to address significant unmet needs in immune-mediated kidney diseases like primary membranous nephropathy and FSGS.
2026-06-02 12:07:00
Travere Therapeutics has secured exclusive rights to develop and commercialize Everest Medicines' experimental kidney disease drug, civorebrutinib, outside of China and parts of Asia. The agreement is valued at up to $1.14 billion, including an upfront payment of $112.5 million and potential milestone payments. Civorebrutinib is an oral BTK inhibitor being developed for rare kidney diseases and is intended to reduce harmful antibodies causing inflammation and damage.
2026-06-02 11:40:08
Travere Therapeutics has signed an exclusive licensing and collaboration agreement with China's Everest Medicines, potentially worth up to $1.1 billion. This deal highlights continued biopharma partnerships between U.S. and Chinese companies.
2026-06-02 11:40:08
Travere Therapeutics has entered into a license and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib, a BTK inhibitor, outside of China and select Asian countries. Travere will make an upfront payment of $112.5 million and Everest Medicines could receive up to $1.03 billion in additional milestone payments. The agreement includes tiered royalties on net sales and a ten-year exclusivity clause.
2026-06-02 11:40:08
Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines. The agreement concerns civorebrutinib, a Btk inhibitor with potential as a best-in-class treatment for rare kidney diseases. The article is a brief announcement of this corporate development.
2026-06-02 10:40:08
Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines for civorebrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor. The deal grants Travere rights to develop and commercialize the drug in territories outside China and certain East and Southeast Asian countries. Travere will pay an upfront fee of $112.5 million, with potential milestone payments up to $1.03 billion and tiered royalties on net sales.
